Table 3 Patient demographics and baseline characteristics from extension study baseline
3003 ApoE ε4 carrier study | 3002 ApoE ε4 noncarrier study | |||||
|---|---|---|---|---|---|---|
PBO + BAP 0.5 (n = 215) | BAP 0.5 + BAP 0.5 (n = 275) | PBO + BAP 0.5 (n = 39) | PBO + BAP 1.0 (n = 37) | BAP 0.5 + BAP 0.5 (n = 66) | BAP 1.0 + BAP 1.0 (n = 56) | |
Mean age (years) | 71.4 | 72.1 | 68.7 | 68.9 | 71.4 | 70.6 |
Femalea (%) | 62.8 | 67.6 | 64.1 | 59.5 | 53.0 | 62.5 |
Whitea (%) | 79.5 | 75.6 | 76.9 | 81.1 | 74.2 | 66.1 |
Asian (%) | 18.1 | 22.9 | 23.1 | 18.9 | 25.8 | 32.1 |
Mean duration of AD (years) | 4.49 | 4.58 | 4.16 | 4.50 | 4.44 | 4.46 |
Mean baseline MMSE | 19.0b | 19.2 | 18.6c | 17.1 | 19.1 | 18.4 |
Current AChEI and/or memantine use, n (%) | ||||||
Yes | 193 (89.8) | 242 (88.0) | 34 (87.2) | 31 (83.8) | 51 (77.3) | 53 (94.6) |
No | 22 (10.2) | 33 (12.0) | 5 (12.8) | 6 (16.2) | 15 (22.7) | 3 (5.4) |